C51/A7401/CRUK_/Cancer Research UK/United Kingdom[Grants and Funding] - Search Results

Year	Number of Results
2008	1
2009	2
2010	1
2013	4
2014	2
2024	0

1

Development of therapeutic combinations targeting major cancer signaling pathways.

Yap TA, Omlin A, de Bono JS. Yap TA, et al. J Clin Oncol. 2013 Apr 20;31(12):1592-605. doi: 10.1200/JCO.2011.37.6418. Epub 2013 Mar 18. J Clin Oncol. 2013. PMID: 23509311 Review.

2

AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.

Grimshaw KM, Hunter LJ, Yap TA, Heaton SP, Walton MI, Woodhead SJ, Fazal L, Reule M, Davies TG, Seavers LC, Lock V, Lyons JF, Thompson NT, Workman P, Garrett MD. Grimshaw KM, et al. Mol Cancer Ther. 2010 May;9(5):1100-10. doi: 10.1158/1535-7163.MCT-09-0986. Epub 2010 Apr 27. Mol Cancer Ther. 2010. PMID: 20423992 Free PMC article.

3

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS. Bianchini D, et al. Eur J Cancer. 2014 Jan;50(1):78-84. doi: 10.1016/j.ejca.2013.08.020. Epub 2013 Sep 25. Eur J Cancer. 2014. PMID: 24074764

4

A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies.

Attard G, Rizzo S, Ledaki I, Clark J, Reid AH, Thompson A, Khoo V, de Bono JS, Cooper CS, Hudson DL. Attard G, et al. Prostate. 2009 Oct 1;69(14):1507-20. doi: 10.1002/pros.20997. Prostate. 2009. PMID: 19544327

5

Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.

Lim AC, Attard G. Lim AC, et al. Curr Drug Targets. 2013 Apr;14(4):408-19. doi: 10.2174/1389450111314040003. Curr Drug Targets. 2013. PMID: 23565754

6

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer.

Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, Seed G, Reid AH, Olmos D, de Bono JS, Attard G. Pezaro C, et al. Br J Cancer. 2013 Jul 23;109(2):325-31. doi: 10.1038/bjc.2013.340. Epub 2013 Jun 27. Br J Cancer. 2013. PMID: 23807167 Free PMC article. Clinical Trial.

7

Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.

Attard G, Jameson C, Moreira J, Flohr P, Parker C, Dearnaley D, Cooper CS, de Bono JS. Attard G, et al. J Clin Pathol. 2009 Apr;62(4):373-6. doi: 10.1136/jcp.2008.061515. Epub 2008 Dec 9. J Clin Pathol. 2009. PMID: 19066166

8

Comparison of three reference methods for the measurement of intracellular pH using 31P MRS in healthy volunteers and patients with lymphoma.

Rata M, Giles SL, deSouza NM, Leach MO, Payne GS. Rata M, et al. NMR Biomed. 2014 Feb;27(2):158-62. doi: 10.1002/nbm.3047. NMR Biomed. 2014. PMID: 24738141 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year